Chiral aspects of the human metabolism of ethosuximide

Biopharmaceutics and Drug Disposition

Volumn 26, Issue 6, 2005, Pages 225-232

  Millership, J S ^a   Mifsud, J ^b   Galea, D ^b   McRoberts, W C ^c   Hamilton, J T G ^c  

^a QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

^b UNIVERSITY OF MALTA   (Malta)

^c AGRI FOOD AND BIOSCIENCES INSTITUTE   (United Kingdom)

Author keywords

Ethosuximide; GC MS; Human metabolism

Indexed keywords

2 (1 HYDROXYETHYL) 2 METHYLSUCCINIMIDE; 2 ETHYL 2 HYDROXYMETHYLSUCCINIMIDE; 2 ETHYL 3 HYDROXY 2 METHYLSUCCINIMIDE; BETA GLUCURONIDASE; CYTOCHROME P450 3A; DRUG METABOLITE; ETHOSUXIMIDE; UNCLASSIFIED DRUG;

ABSENCE; ARTICLE; CHIRAL CHROMATOGRAPHY; CHIRALITY; CLINICAL ARTICLE; DRUG IDENTIFICATION; DRUG METABOLISM; DRUG STRUCTURE; DRUG URINE LEVEL; ENANTIOMER; GAS CHROMATOGRAPHY; HUMAN; MASS SPECTROMETRY; STEREOISOMERISM; TREATMENT INDICATION;

ANTICONVULSANTS; ETHOSUXIMIDE; GAS CHROMATOGRAPHY-MASS SPECTROMETRY; HUMANS;

EID: 25144519354     PISSN: 01422782     EISSN: None     Source Type: Journal    
DOI: 10.1002/bdd.454     Document Type: Article

References (13)

1. Dill WA, Peterson L, Chang T, Glazko AJ. Physiological disposition of α-methyl-α-ethylsuccinimide (ethosuximide, Zarontin®) in animals and in man. In Proceedings of 149th National Meeting, American Chemical Society: Detroit, Michigan, Washington, 1965; 30N.
2. Burkett AR, Chang T, Glazko AJ. A hydroxylated metabolite of ethosuximide (Zarontin®) in rat urine. Fed Proc 1971; 30: 91.
3. Chang T, Burkett AR, Glazko AJ. Ethosuximide - biotransformation. In Antiepileptic Drugs, Woodbury DM, Penry JK, Schmidt RP (eds), 1st edn. Raven Press: New York, 1972, 425-429.
4. Horning MG, Stratton C, Nowlin J, Harvey DJ, Hill RM. Metabolism of 2-ethyl-2-methylsuccinimide (ethosuximide) in the rat and human. Drug Metab Dispos 1973; 1: 569-576.
5. Chang T, Burkett AR. Ethosuximide - biotransformation. In Antiepileptic Drugs, Woodbury DM, Penry JK, Schmidt RP (eds), 2nd edn. Raven Press: New York, 1982; 631-635.
6. Preste PG, Westerman CE, Das NP, Wilder BJ, Duncan JH. Identification of 2-ethyl-2-methyl-3-hydroxy succinimide as a major metabolite of ethosuximide in humans. J Pharm Sci 1974; 63: 467-469.
7. Goulet JR, Kinkel AW, Smith TC. Metabolism of ethosuximide. Clin Pharm Ther 1976; 20(2): 213-218.
8. Petterson JE. Urinary metabolites of 2-ethyl-2-methylsuccinimide (ethosuximide) studied by combined gas chromatography mass spectrometry. Biomed Mass Spectrom 1978; 5: 601-603.
9. Villen T, Bertilsson L, Sjoqvist F. Nonstereoselective disposition of ethosuximide in humans. Ther Drug Monit 1990; 12: 514-516.
10. Millership JS, Mifsud J, Collier PS. The metabolism of ethosuximide. Eur J Drug Metab Pharmacokinet 1993; 18: 349-353.
11. Millership JS, Collier PS, Hamilton JTG, McRoberts WC, Mifsud J. Chiral aspects of the metabolism of ethosuximide. Chirality 1995; 7: 173-180.
12. Mifsud J, Millership JS, Collier PS, Morrow R, Hamilton JTG, McRoberts WC. Quantification of urinary excretion of ethosuximide enantiomers and their major metabolites in the rat. Biopharm Drug Dispos 2001; 22: 129-136.
13. Bachmann Kin, He Y, Sarver JG, Ping N. Characterization of the cytochrome P450 enzymes involved in the in vitro metabolism of ethosuximide by human hepatic microsomal enzymes. Xenobiotica 2003; 33: 265-276.